Expansion of Dermatology Portfolio Using an Evidence-Based Approach
A pharmaceutical client requested evidence-based priorities and target product profile characteristics to guide priorities for their dermatology portfolio.
Certara conducted in-depth interviews with ten US commercial and Medicare payers.
From a portfolio view, Certara helped our client guide and accelerate their clinical development by assessing and prioritizing value drivers across efficacy, safety, dosing, and cost parameters. This enabled them to bring forward a stronger product concept, reducing investment and time to market.
After conducting and analyzing the interviews, Certara;
Identified efficacy / safety endpoints and additional economic data that would drive value to payers
Provided a comprehensive assessment of each product concept by payers
Defined a price range for each product concept and expected formulary access
Assessed payers’ future priorities in managing and funding treatments for patients in this therapeutic category and identified how this will affect access to the products tested
Identified products to prioritize based on payer assessment